Investing in stocks that aren't performing well can be a good move, but only if there are good reasons to think they will recover. That isn't the case for many companies that have lagged broader ...
The Gross Law Firm issues the following notice to shareholders of Regeneron Pharmaceuticals, Inc. . Shareholders who purchased ...
In a report released on February 7, Cory Kasimov from Evercore ISI maintained a Buy rating on Regeneron (REGN – Research Report), with a price ...
Bayer submitted an application to the European Medicines Agency (EMA) to expand treatment intervals of up to 6 months with Eyleaâ„¢ 8 mg (aflibercept 8 mg, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results